Pre-exposure prophylaxis for the prevention of HIV infection in high risk populations: A meta-analysis of randomized controlled trials

PLoS ONE

Volumn 9, Issue 2, 2014, Pages

  Jiang, Junjun ^a   Yang, Xiaoyi ^a   Ye, Li ^a   Zhou, Bo ^a   Ning, Chuanyi ^a   Huang, Jiegang ^a   Liang, Bingyu ^a   Zhong, Xiaoni ^b   Huang, Ailong ^b   Tao, Renchuan ^a   Cao, Cunwei ^a   Chen, Hui ^a   Liang, Hao ^a  

^a GUANGXI MEDICAL UNIVERSITY   (China)

^b CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; EMTRICITABINE; TENOFOVIR DISOPROXIL; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; FEMALE; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RATE; MALE; META ANALYSIS; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; RISK REDUCTION; VIRUS TRANSMISSION; HIV INFECTIONS; OUTCOME ASSESSMENT; PREVENTIVE MEDICINE; PROCEDURES; STATISTICS AND NUMERICAL DATA; TRANSMISSION;

ANTI-HIV AGENTS; HIV INFECTIONS; HUMANS; OUTCOME ASSESSMENT (HEALTH CARE); PREVENTIVE MEDICINE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS;

EID: 84896809128     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0087674     Document Type: Review

References (43)

1. Global report: UNAIDS report on the global AIDS epidemic 2012. UNAIDS website. Available:. http://www.unaids.org/en/media/unaids/contentassets/ documents/epidemiology/2012/gr2012/20121120-UNAIDS-Global-Report-2012-with- annexes-en.pdf. Accessed 2013 Oct. 16.
2. D'Cruz OJ, Uckun FM (2006) Novel broad-spectrum thiourea non-nucleoside inhibitors for the prevention of mucosal HIV transmission. Curr HIV Res 4: 329-345. (Pubitemid 44027722)
3. Hirbod T, Broliden K (2007) Mucosal immune responses in the genital tract of HIV-1-exposed uninfected women. J Intern Med 262: 44-58. (Pubitemid 47000632)
4. Kim SC, Becker S, Dieffenbach C, Hanewall BS, Hankins C, et al. (2010) Planning for pre-exposure prophylaxis to prevent HIV transmission: challenges and opportunities. J Int AIDS Soc 13: 24.
5. Padian NS, Buve A, Balkus J, Serwadda D, Cates W (2008) HIV prevention 2 - Biomedical interventions to prevent HIV infection: evidence, challenges, and way forward. Lancet 372: 585- 599.
6. Grant RM, Buchbinder S, Cates W, Jr., Clarke E, Coates T, et al. (2005) AIDS. Promote HIV chemoprophylaxis research, don't prevent it. Science 309: 2170-2171. (Pubitemid 41396056)
7. Liu AY, Kittredge PV, Vittinghoff E, Raymond HF, Ahrens K, et al. (2008) Limited knowledge and use of HIV post- and pre-exposure prophylaxis among gay and bisexual men. Jaids-Journal of Acquired Immune Deficiency Syndromes 47: 241-247. (Pubitemid 351172193)
8. Youle M, Wainberg MA (2003) Could chemoprophylaxis be used as an HIV prevention strategy while we wait for an effective vaccine? Aids 17: 937-938. (Pubitemid 36547674)
9. Paxton LA, Hope T, Jaffe HW (2007) Pre-exposure prophylaxis for HIV infection: what if it works? Lancet 370: 89-93. (Pubitemid 47033881)
10. Cohen MS, Gay C, Kashuba AD, Blower S, Paxton L (2007) Narrative review: antiretroviral therapy to prevent the sexual transmission of HIV-1. Ann Intern Med 146: 591-601. (Pubitemid 351650540)
11. Derdelinckx I, Wainberg MA, Lange JMA, Hill A, Halima Y, et al. (2006) Criteria for drugs used in pre-exposure prophylaxis trials against HIV infection. Plos Medicine 3: 1999-2004. (Pubitemid 44875935)
12. Liu AY, Grant RM, Buchbinder SP (2006) Preexposure prophylaxis for HIV: unproven promise and potential pitfalls. JAMA 296: 863-865. (Pubitemid 44223110)
13. Rosen RK, Morrow KM, Carballo-Dieguez A, Mantell JE, Hoffman S, et al. (2008) Acceptability of tenofovir gel as a vaginal microbicide among women in a phase I trial: A mixed-methods study. Journal of Womens Health 17: 383-392. (Pubitemid 351457833)
14. Garcia-Lerma JG, Otten RA, Qari SH, Jackson E, Cong ME, et al. (2008) Prevention of rectal SHIV transmission in macaques by daily or intermittent prophylaxis with emtricitabine and tenofovir. PLoS Med 5: e28.
15. Subbarao S, Otten RA, Ramos A, Kim C, Jackson E, et al. (2006) Chemoprophylaxis with tenofovir disoproxil fumarate provided partial protection against infection with simian human immunodeficiency virus in macaques given multiple virus challenges. J Infect Dis 194: 904-911. (Pubitemid 44454075)
16. Van Rompay KK, Kearney BP, Sexton JJ, Colon R, Lawson JR, et al. (2006) Evaluation of oral tenofovir disoproxil fumarate and topical tenofovir GS-7340 to protect infant macaques against repeated oral challenges with virulent simian immunodeficiency virus. J Acquir Immune Defic Syndr 43: 6-14. (Pubitemid 44306481)
17. Abbas UL, Anderson RM, Mellors JW (2007) Potential impact of antiretroviral chemoprophylaxis on HIV-1 transmission in resource-limited settings. PLoS One 2: e875.
18. Li Q, Estes JD, Schlievert PM, Duan L, Brosnahan AJ, et al. (2009) Glycerol monolaurate prevents mucosal SIV transmission. Nature 458: 1034-1038.
19. Paltiel AD, Freedberg KA, Scott CA, Schackman BR, Losina E, et al. (2009) HIV preexposure prophylaxis in the United States: impact on lifetime infection risk, clinical outcomes, and cost-effectiveness. Clin Infect Dis 48: 806-815.
20. Okwundu CI, Uthman OA, Okoromah CA (2012) Antiretroviral pre-exposure prophylaxis (PrEP) for preventing HIV in high-risk individuals. Cochrane Database Syst Rev 7: CD007189.
21. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, et al. (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17: 1-12. (Pubitemid 26120810)
22. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7: 177-188. (Pubitemid 17189972)
23. MAI Jinzhuang, LI He, FANG Jiqian, et al (2006) Estimation of Fail-Safe Number in Meta-Analysis. The Journal of Evidence-Based Medicine 6: 297-303.
24. Baeten J, Celum C (2011) Antiretroviral pre-exposure prophylaxis for HIV-1 prevention among heterosexual African men and women: the Partners PrEP study. 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention. Rome.
25. Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, et al. (2010) Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 329: 1168-1174.
26. Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, et al. (2010) Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 363: 2587-2599.
27. Peterson L, Taylor D, Roddy R, Belai G, Phillips P, et al. (2007) Tenofovir disoproxil fumarate for prevention of HIV infection in women: a phase 2, double-blind, randomized, placebo-controlled trial. PLoS Clin Trials 2: e27.
28. Thigpen MC, Kebaabetswe PM, Paxton LA, Smith DK, Rose CE, et al. (2012) Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med 367: 423-434.
29. Van Damme L, Corneli A, Ahmed K, Agot K, Lombaard J, et al. (2012) Preexposure Prophylaxis for HIV Infection among African Women. New England Journal of Medicine 367: 411-422.
30. Choopanya K, Martin M, Suntharasamai P, Sangkum U, Mock PA, et al. (2013) Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. The Lancet 381: 2083-2090.
31. Thigpen MC, Kebaabetswe PM, Smith DK, Segolodi TM, Soud FA, et al. (2011) Daily oral antiretroviral use for the prevention of HIV infection in heterosexually active young adults in Botswana. 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention Rome.
32. Chirenje ZM, Marrazzo J (2012) Safety and Effectiveness of Tenofovir 1% Gel, Tenofovir Disproxil Fumarate, and Emtricitabine/Tenofovir Disoproxil Fumarate Tablets in Preventing HIV in Women.
33. Grant RM Use of Emtricitabine and Tenofovir Disoproxil Fumarate for Pre-Exposure Prophylaxis (ADAPT).
34. Evaluating the Safety and Tolerability of Antiretroviral Drug Regimens Used as Pre-Exposure Prophylaxis to Prevent HIV Infection in Men Who Have Sex With Men (HPTN 069).
35. Molina J On Demand Antiretroviral Pre-exposure Prophylaxis for HIV Infection in Men Who Have Sex With Men (IPERGAY).
36. Berger RE (2011) Re: Effectiveness and Safety of Tenofovir Gel, an Antiretroviral Microbicide, for the Prevention of HIV Infection in Women. J Urol 185: 1729.
37. Karim QA, Kharsany AB, Frohlich JA, Baxter C, Yende N, et al. (2011) Recruitment of high risk women for HIV prevention trials: baseline HIV prevalence and sexual behavior in the CAPRISA 004 tenofovir gel trial. Trials 12: 67.
38. Martin M, Vanichseni S, Suntharasamai P, Sangkum U, Chuachoowong R, et al. (2011) Enrollment characteristics and risk behaviors of injection drug users participating in the Bangkok Tenofovir Study, Thailand. PLoS One 6: e25127.
39. Mujugira A, Baeten JM, Donnell D, Ndase P, Mugo NR, et al. (2011) Characteristics of HIV-1 serodiscordant couples enrolled in a clinical trial of antiretroviral pre-exposure prophylaxis for HIV-1 prevention. PLoS One 6: e25828.
40. Mutua G, Sanders E, Mugo P, Anzala O, Haberer JE, et al. (2012) Safety and adherence to intermittent pre-exposure prophylaxis (PrEP) for HIV-1 in African men who have sex with men and female sex workers. PLoS One 7: e33103.
41. Kumwenda NI, Hoover DR, Mofenson LM, Thigpen MC, Kafulafula G, et al. (2008) Extended antiretroviral prophylaxis to reduce breast-milk HIV-1 transmission. N Engl J Med 359: 119-129. (Pubitemid 351962035)
42. Siegfried N, van der Merwe L, Brocklehurst P, Sint TT (2011) Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection. Cochrane Database Syst Rev: CD003510.
43. Baeten J, Celum C (2012) Systemic and topical drugs for the prevention of HIV infection: antiretroviral pre-exposure prophylaxis. Annu Rev Med.